Patents Assigned to Alkermes Pharma Ireland Limited
  • Methods for treating antipsychotic-induced weight gain
    Patent number: 9517235
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: December 13, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Prodrugs of fumarates and their use in treating various diseases
    Patent number: 9505776
    Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 29, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
  • Compositions of buprenorphine and ? Antagonists
    Patent number: 9498474
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 22, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Aripiprazole formulations having increased injection speeds
    Patent number: 9452131
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: September 27, 2016
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Magali B. Hickey, Jennifer Vandiver
  • Morphan and morphinan analogues, and methods of use
    Patent number: 9416137
    Abstract: The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: August 16, 2016
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
  • REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
    Publication number: 20160228555
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
    Publication number: 20160228554
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Polymorphic forms of naltrexone
    Patent number: 9365580
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 14, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Pharmaceutical compositions comprising sorbitan esters
    Patent number: 9351976
    Abstract: The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 31, 2016
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver
  • Reduction of flake-like aggregation in nanoparticulate active agent compositions
    Patent number: 9345665
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: May 24, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • ARIPIPRAZOLE PRODRUG COMPOSITIONS
    Publication number: 20160045495
    Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.
    Type: Application
    Filed: August 17, 2015
    Publication date: February 18, 2016
    Applicant: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Philip CRESSWELL, Sara Montminy Paquette, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Ryan Turncliff, Michael Palmieri, Tarek Zeidan, Ethan P. Cash, Marjie L. Hard
  • Polymer-based sustained release device
    Patent number: 9238076
    Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: January 19, 2016
    Assignees: Alkermes Pharma Ireland Limited, Amylin Pharmaceuticals, LLC
    Inventors: Steven G. Wright, Troy Christensen, Thean Yeoh, Michael E. Rickey, Joyce M. Hotz, Rajesh Kumar, Mark Fineman, Christine Smith, John Ong, David M. Lokensgard, Henry R. Costantino
  • Polymorphic forms of naltrexone
    Patent number: 9221830
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: December 29, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Opioid agonist antagonist combinations
    Patent number: 9211293
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: December 15, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Pharmaceutical compositions having improved storage stability
    Patent number: 9193685
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: November 24, 2015
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
  • NANOPARTICULATE MEGESTROL FORMULATIONS
    Publication number: 20150320682
    Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: May 15, 2015
    Publication date: November 12, 2015
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Douglas Hovey, John Pruitt, Tuula Ryde
  • Morphan and morphinan analogues, and methods of use
    Patent number: 9133125
    Abstract: The present application relates to analogs of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: September 15, 2015
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Laura Cook Blumberg, Dan Deaver, David Eyerman
  • Abuse resistant pharmaceutical compositions
    Patent number: 9132096
    Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: September 15, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell
  • Drug delivery device
    Patent number: 9132231
    Abstract: A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to undergo incremental advancement. The device may also be provided with manual control for delivering a bolus dose of drug when necessary.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: September 15, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Joseph Gross, Izrail Tsals, Gilad Lavi, Gil Yigal, Ehoud Carmel
  • Methods for treating antipsychotic-induced weight gain
    Patent number: 9126977
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: September 8, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Mark Todtenkopf